Format

Send to

Choose Destination
Eur Heart J. 2018 Nov 21;39(44):3973-3979. doi: 10.1093/eurheartj/ehy413.

Continued vs. interrupted direct oral anticoagulants at the time of device surgery, in patients with moderate to high risk of arterial thrombo-embolic events (BRUISE CONTROL-2).

Author information

1
Department of Medicine, University of Ottawa, University of Ottawa Heart Institute, 40 Ruskin St., Ottawa, ON, Canada.
2
Hamilton Health Sciences, Population Health Research Institute, McMaster University, 237 Barton St. East, Hamilton, ON, Canada.
3
Hopital Fleurimont, Universite de Sherbrooke, 3001 12e Ave Nord, Sherbrooke, QC, Canada.
4
Centre Hospitalier de L'Universite de Montreal, Hopital Hotel-Dieu, 850 St-Denis St., Montreal, QC, Canada.
5
Libin Cardiovascular Institute, Foothills Medical Centre, University of Calgary, 1403 29th St. NW, Calgary, AB, Canada.
6
Hôpital du Sacré-Coeur de Montréal, 5400 boul Gouin Ouest, Montreal, QC, Canada.
7
Southlake Regional Health Center, 581 Davis Dr, Newmarket, ON, Canada.
8
Institut Universitaire de Cardiologie et de Pneumologie de Quebec, Laval University, 2725 chemin Ste-Foy, QC, Canada.
9
Galilee Medical Center, 1 Ben Tzvi Blvd, Nahariya, Israel.
10
University of Alberta, 8440 112 St, Edmonton, AB, Canada.
11
Service de Cardiologie, Hopital Henri Mondor, APHP, Creteil, France.
12
QEII Health Sciences Centre, Dalhousie University, Halifax, NS, Canada.
13
McGill University Health Center, McGill University, and Hôpital Sacré-Coeur de Montréal, Montreal, QC, Canada.

Abstract

Aims:

Guidelines recommend warfarin continuation rather than heparin bridging for pacemaker and defibrillator surgery, after the BRUISE CONTROL trial demonstrated an 80% reduction in device pocket haematoma with this approach. However, direct oral anticoagulants (DOACs) are now used to treat the majority of patients with atrial fibrillation. We sought to understand the best strategy to manage the DOACs at the time of device surgery and specifically hypothesized that performing device surgery without DOAC interruption would result in a reduced haematoma rate.

Methods and results:

We randomly assigned patients with atrial fibrillation and CHA2DS2-VASc score ≥2, to continued vs. interrupted DOAC (dabigatran, rivaroxaban, or apixaban). The primary outcome was blindly evaluated, clinically significant device pocket haematoma: resulting in re-operation, interruption of anticoagulation, or prolonging hospital stay. In the continued arm, the median time between pre- and post-operative DOAC doses was 12 h; in the interrupted arm the median time was 72 h. Clinically significant haematoma occurred in of 7 of 328 (2.1%; 95% CI 0.9-4.3) patients in the continued DOAC arm and 7 of 334 (2.1%; 95% CI 0.9-4.3) patients in the interrupted DOAC arm (P = 0.97). Complications were uncommon, and included one stroke and one symptomatic pericardial effusion in each arm.

Conclusions:

These results suggest that, dependent on the clinical scenario, either management strategy (continued DOAC or interrupted DOAC) might be reasonable, at least for patients similar to those enrolled in our trial.

PMID:
30462279
DOI:
10.1093/eurheartj/ehy413

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center